FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an isolated agonistic antibody against lymphocyte activation gene-3 (LAG-3) and its antigen-binding fragment, as well as to a composition containing it. Nucleic acid encoding the specified antibody or its fragment, as well as a vector and a cell containing it are also disclosed.
EFFECT: invention is effective for the treatment of an immune disorder mediated by T cells.
64 cl, 31 dwg, 36 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES FOR TREATMENT OF HEPATITIS B INFECTION AND RELATED DISEASES | 2018 |
|
RU2765878C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
| ANTI-CD112R ANTIBODY COMPOSITIONS AND RELATED METHODS | 2019 |
|
RU2819624C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| NECTIN-4 BINDING PROTEINS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2805252C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| ANTIBODY SPECIFICALLY BINDING TO PAUF PROTEIN, AND ITS USE | 2017 |
|
RU2735102C1 |
